Alexander Sapir
Förmögenhet: 735 364 $ per 2026-06-30
Förmögenhet: 735 364 $ per 2026-06-30
Mr. Alexander C.
Sapir is a President, Chief Executive Officer & Director at Fulcrum Therapeutics, Inc., an Independent Director at PhaseBio Pharmaceuticals, Inc. and a Chief Executive Officer & Director at ReViral Ltd. He is on the Board of Directors at Fulcrum Therapeutics, Inc., PhaseBio Pharmaceuticals, Inc. and ReViral Ltd. Mr. Sapir was previously employed as a President, Chief Executive Officer & Director by Dova Pharmaceuticals, Inc., an Executive Vice President-Marketing & Sales by United Therapeutics Corp., and a Senior Director-Marketing by Guilford Pharmaceuticals, Inc. He received his undergraduate degree from Franklin & Marshall College and an MBA from Harvard Business School.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
| 2026-03-31 | 200 919 ( 0,3 % ) | 735 364 $ | 2026-06-30 |
| Företag | Position | Start |
|---|---|---|
| PHASEBIO PHARMACEUTICALS, INC. | Direktör/Styrelseledamot | 2020-02-12 |
| FULCRUM THERAPEUTICS, INC. | Verkställande Direktör | 2023-07-01 |
ReViral Ltd.
ReViral Ltd. BiotechnologyHealth Technology Develops novel antiviral therapeutics | Verkställande Direktör | 2019-06-10 |
| Företag | Position | Slut |
|---|---|---|
| DOVA PHARMACEUTICALS, INC. | Verkställande Direktör | 2018-12-01 |
| UNITED THERAPEUTICS CORPORATION | Försäljning & Marknadsföring | 2016-05-01 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs used to treat neurological diseases | Försäljning & Marknadsföring | 2005-01-01 |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 8 |
|---|---|
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs used to treat neurological diseases | Health Technology |
United Therapeutics Corp.
United Therapeutics Corp. BiotechnologyHealth Technology Operates as a biotechnology company that develops and commercializes products to address the unmet medical needs of patients with chronic & life-threatening conditions | Health Technology |
PhaseBio Pharmaceuticals, Inc.
PhaseBio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of novel therapies for cardiovascular diseases | Health Technology |
Franklin & Marshall College
Franklin & Marshall College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ReViral Ltd.
ReViral Ltd. BiotechnologyHealth Technology Develops novel antiviral therapeutics | Health Technology |
Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicines for patients by transforming gene regulation in disease | Health Technology |
Dova Pharmaceuticals, Inc.
Dova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes drugs with disorder of low blood platelet count | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån